New IBS drug in development in Japan
07/05/06 05:13 PM
TOKYO, July 3 (Reuters) - Astellas Pharma , Japan's third-biggest drug maker, said on Monday it would give highest development priority to three new medicines.
Newly appointed president Masafumi Nogimori told a news conference on the company's research and development that Astellas will aim for speedy development of YM060 to treat irritable bowel syndrome, YM150 to prevent thromboembolism and YM311 treatment of renal anaemia and anaemia of cancer.
YM060, which the company sees as more effective in diarrhoea and lower bowel symptoms than competitors' products, is being filed for approval in Japan and is in phase II trials in Europe.